Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The vacuolar H+ ATPase (V-ATPase) is a proton pump responsible for acidification of cellular microenvironments, an activity exploited by tumors to survive, proliferate and resist to therapy. Despite few observations, the role of V-ATPase in human tumorigenesis remains unclear.We investigated the expression of ATP6V0C, ATP6V0A2, encoding two subunits belonging to the V-ATPase V0 sector and ATP6V1C, ATP6V1G1, ATPT6V1G2,
ATP6V1G3
, which are part of the V1 sector, in series of adult gliomas and in cancer stem cell-enriched neurospheres isolated from
glioblastoma
(
GBM
) patients. ATP6V1G1 expression resulted significantly upregulated in tissues of patients with
GBM
and correlated with shorter patients' overall survival independent of clinical variables.ATP6V1G1 knockdown in
GBM
neurospheres hampered sphere-forming ability, induced cell death, and decreased matrix invasion, a phenotype not observed in
GBM
monolayer cultures. Treating
GBM
organotypic cultures or neurospheres with the selective V-ATPase inhibitor bafilomycin A1 reproduced the effects of ATP6V1G1 siRNA and strongly suppressed expression of the stem cell markers Nestin, CD133 and transcription factors SALL2 and POU3F2 in neurospheres.These data point to ATP6V1G1 as a novel marker of poor prognosis in
GBM
patients and identify V-ATPase inhibition as an innovative therapeutic strategy for
GBM
.
...
PMID:The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma. 2602 Aug 5